SILVER SPRING, Md., June 3, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration is alerting health care providers to no longer implant end-stage heart failure patients with Medtronic's ...

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

Approximately one year after the company landed FDA approval for its Ventricular Assist System, the company is boasting significant surge in revenue. In early morning trading on November 7, the ...

With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.

Please provide your email address to receive an email when new articles are posted on . The FDA and Medtronic alerted health care providers to no longer implant patients with end-stage HF with a ...

Findings from the first-in-human trial of a novel percutaneous ventricular assist device (pVAD) were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & ...

(RTTNews) - Medical devices maker Medtronic plc (MDT) will stop the distribution and sale of the Medtronic Heartware Ventricular Assist Device (HVAD) System. It has also notified physicians to cease ...

Pediatric ventricular assist devices (VADs) and mechanical circulatory support systems have emerged as critical tools in the management of children with end‐stage heart failure, including those with ...

HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, ...

The DuraHeart Left-Ventricular Assist System, or “LVAS,” from Terumo Heart was featured at a recent health technology event. DuraHeart LVAS is a next-generation medical device designed to help sustain ...